Russell Investments Group
BTAI icon

Russell Investments Group’s BioXcel Therapeutics BTAI Stock Holding History

Russell Investments Group’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-22
Closed -$970 – 3586
2024
Q1 		$970 Buy
22
+16
+267% +$763 ﹤0.01% 3136
2023
Q4 		$260 Buy
+6
New +$334 ﹤0.01% 3166
2023
Q2 		– Sell
-13
Closed -$3.88K – 3458
2023
Q1 		$3.88K Buy
+13
New +$5.55K ﹤0.01% 2965
2021
Q3 		– Sell
-40
Closed -$18K – 3055
2021
Q2 		$18K Sell
40
-1,212
-97% -$661K ﹤0.01% 3177
2021
Q1 		$862K Sell
1,252
-121
-9% -$97.3K ﹤0.01% 2307
2020
Q4 		$1.02M Buy
1,373
+756
+123% +$589K ﹤0.01% 2111
2020
Q3 		$426K Hold
617
– – ﹤0.01% 2460
2020
Q2 		$521K Sell
617
-609
-50% -$397K ﹤0.01% 2365
2020
Q1 		$440K Buy
+1,226
New +$441K ﹤0.01% 2231

Other funds holding BTAI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Russell Investments Group's BTAI Position: Q2 2024 in Review

Russell Investments Group sold out of BioXcel Therapeutics (BTAI) in Q2 2024, closing a stake of 22 shares — an estimated $970 sold.

Russell Investments Group first reported a position in BTAI in Q1 2020 and held it in 9 quarters. The position peaked at $1.02M in Q4 2020. 74 funds tracked by Wall St. Rank hold BTAI as of Q2 2024.

  • Russell Investments Group reported no remaining BioXcel Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Russell Investments Group sold 22 BioXcel Therapeutics shares in Q2 2024, an estimated $970.
  • Russell Investments Group first reported a position in BioXcel Therapeutics in Q1 2020 and held it in 9 quarters.
  • Russell Investments Group's BioXcel Therapeutics position peaked at $1.02M in Q4 2020.
  • 74 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2024.

Based on Russell Investments Group's 13F filing for Q2 2024, filed 8 Aug 2024.